Senate Judiciary Committee Chairman Chuck Grassley Charles (Chuck) Ernest GrassleyGOP set to release controversial Biden report McConnell locks down key GOP votes in Supreme Court fight Senate Republicans face tough decision on replacing Ginsburg MORE (R-Iowa) on Thursday said that the maker of EpiPens had not gone far enough in taking steps to reduce the injectors' price and continued to press the company for answers about a price hike.

ADVERTISEMENT

Facing an uproar about the 400 percent increase in the price of the treatment for serious allergic reactions in recent years, EpiPen maker Mylan on Thursday announced steps to reduce the price by providing a savings card worth up to $300 to people facing the full out-of-pocket cost.

But Grassley and other lawmakers have noted that this step is short of actually reducing the drug's sticker price, only applies to some people and could still leave programs like Medicare and Medicaid paying a high cost.

“The announcement today doesn’t appear to change the product price,” Grassley, who is being targeted by Democrats in his reelection race this year, said in a statement. “The price is what Medicare, Medicaid and insurance companies pay. It’s what patients who don’t get assistance cards pay. And when drug companies offer patient assistance cards, it’s usually not clear how many patients benefit.”

Grassley added that he still expects the company to respond to a letter he sent on Monday pressing for answers on why the price increase was justified.

Rep. Elijah Cummings (Md.), the top Democrat on the House Oversight Committee, struck a harsher tone on Thursday, calling Mylan’s announcement simply a “PR move.”

"Mylan should not offer after-the-fact discounts only for a select few — it should reverse its massive price increases across the board immediately," Cummings said in a statement.